Saturday, 03 December 2022
- Welcome Guest
- Media Kit INR
- Subscribe
- Newsletter
- Infographics
- Login/Sign Up
LIVE
Video
TRENDING NEWS
- POLICY & REGULATORY
-
CDSCO approves AstraZeneca’s anti-diabetic drug Dapagliflozin with additional indications
Bharat Biotech's intranasal vaccine iNCOVACC receives heterologous booster approval
Ministry of Ayush inks MoU with Department of Science and Technology
- BIOMONEY
-
Gland Pharma buys Cenexi Group for €120 M
Mankind Pharma acquires majority stake in Upakarma Ayurveda
ACT invests Rs 3.2 Cr towards catalysing accessible & affordable cancer care in India
- PHARMA
-
Indian Immunologicals first to venture into fish vaccines
Indian Immunologicals transports animal vaccines through drones
Novo Nordisk to improve healthcare access for patients with diabetes, obesity in Karnataka
- WORLD
-
WHO recommends new name for monkeypox disease
US establishes website for self-reporting COVID-19 test results
WHO to identify pathogens likely to cause future outbreaks and pandemics
-
Science | 28 November 2022 | News
Karnataka State Council for Science and Technology receives special recognition
Karnataka Government has announced that more than 700 patents have been filed by Karnataka State Council for S...Read more
-
Opinion | 30 November 2022 | Views
A Pharma Lens: Looking Back at 2022
In the past three years, we have witnessed the pharma giants stepping up to the occasion, by becoming innovati...Read more
-
MedTech | 18 November 2022 | News
Swedish medtech firm C-RAD sets up India Experience Centre for Precision Radiotherapy
Swedish medtech company C-RAD, the global leader in surface guided radiation therapy (SGRT) solutions, has est...Read more
-
Medical Diagnostic | 30 November 2022 | News
Mylab unveils indigenous TB and multi-drug resistance detection kit
Pune-based startup Mylab has received CDSCO, TB Expert Committee and ICMR approval for first Made in India tub...Read more
-
Supplier | 30 November 2022 | Features
A single-use system (SUS) is biopharmaceutical manufacturing (bioprocessing) equipment that is designed to be ...Read more
-
People | 29 November 2022 | News
MSD India appoints Bhargavi Kakunuri as Human Resources Lead
MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) has announced Bhargavi Kakunuri’ s appointme...Read more
-
Academics | 29 November 2022 | News
IIM Raipur inks MoU with Digital Health Academy for launching new online course
A Memorandum of Understanding (MoU) has been signed between Digital Health Academy (an SBU of Digital Health A...Read more
-
Blogs | 08 May 2022 | Views
Returning Mothers: Upskilling Their Way in Their Career
Whether you are a mother who has been out of the workplace for one year or ten years, the thought of restartin...Read more
Videos
Inside Magazine
Can INDIA Dethrone CHINA In API PRODUCTION?
The past decade has witnessed steady growth and commitment of the Indian government in addressing issues like ‘self-reliance and self-sufficiency in all aspects of governance and decisions. While sops and subsidies were, indeed, crucial to many concerns of industries and stakeholders, key decisions and schemes were lacking, until numerous ‘Aatmanirbhar Projects’ were kicked off by the Centre. One such crucial initiative addresses the need for Bulk Drugs Parks in India, making the country less dependent on Chinese Active Pharmaceutical Ingredients (APIs), providing more employment, and generating more revenue that will add to the country’s GDP. A laudable step has been taken with the launching of three Bulk Drugs projects across three states in the country, with an estimated time of completion set at 5 years. We shall take a closer look at what the project entails and seek expert views from a few industry stalwarts.
For Feedback, please email us at: communications@mmactiv.com
BioSpectrum Infomercial
